KR20030032940A - 신규 화합물 - Google Patents

신규 화합물 Download PDF

Info

Publication number: KR20030032940A
Authority: KR; South Korea
Prior art keywords: polypeptide; sequence; polynucleotide; polypeptides; diseases
Prior art date: 2000-04-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

KR1020027014463A

Other languages

English (en)

Korean (ko)

Inventor

판카 아가왈

폴 알. 머독

사피아 케이. 리즈비

란달 에프. 스미쓰

자오잉 시앙

카렌 에스. 카브닉

잉-타 라이

칭 시에

Original Assignee

스미스클라인 비참 코포레이션

스미스클라인비이참피이엘시이

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-27

Filing date

2001-04-26

Publication date

2003-04-26

2001-04-26 Application filed by 스미스클라인 비참 코포레이션, 스미스클라인비이참피이엘시이 filed Critical 스미스클라인 비참 코포레이션

2003-04-26 Publication of KR20030032940A publication Critical patent/KR20030032940A/ko

Status Withdrawn legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 title description 17
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 224
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 217
229920001184 polypeptide Polymers 0.000 claims abstract description 214
108091033319 polynucleotide Proteins 0.000 claims abstract description 137
102000040430 polynucleotide Human genes 0.000 claims abstract description 137
239000002157 polynucleotide Substances 0.000 claims abstract description 136
108090000623 proteins and genes Proteins 0.000 claims abstract description 121
238000000034 method Methods 0.000 claims abstract description 68
210000004027 cell Anatomy 0.000 claims description 59
238000004519 manufacturing process Methods 0.000 claims description 11
230000000295 complement effect Effects 0.000 claims description 7
210000000170 cell membrane Anatomy 0.000 claims description 5
238000003306 harvesting Methods 0.000 claims description 2
239000013604 expression vector Substances 0.000 claims 2
238000012258 culturing Methods 0.000 claims 1
238000003556 assay Methods 0.000 abstract description 9
238000010188 recombinant method Methods 0.000 abstract description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 71
201000010099 disease Diseases 0.000 description 68
102000004169 proteins and genes Human genes 0.000 description 48
235000018102 proteins Nutrition 0.000 description 46
206010028980 Neoplasm Diseases 0.000 description 38
201000011510 cancer Diseases 0.000 description 37
125000003729 nucleotide group Chemical group 0.000 description 36
239000002773 nucleotide Substances 0.000 description 35
230000014509 gene expression Effects 0.000 description 32
108091032973 (ribonucleotides)n+m Proteins 0.000 description 29
108020004414 DNA Proteins 0.000 description 28
208000023275 Autoimmune disease Diseases 0.000 description 25
239000012634 fragment Substances 0.000 description 24
208000015181 infectious disease Diseases 0.000 description 23
230000029663 wound healing Effects 0.000 description 23
241000282414 Homo sapiens Species 0.000 description 22
150000001413 amino acids Chemical class 0.000 description 22
208000018706 hematopoietic system disease Diseases 0.000 description 22
238000011282 treatment Methods 0.000 description 21
230000000694 effects Effects 0.000 description 20
239000002299 complementary DNA Substances 0.000 description 17
239000013615 primer Substances 0.000 description 17
239000013598 vector Substances 0.000 description 16
241001465754 Metazoa Species 0.000 description 15
238000012216 screening Methods 0.000 description 15
125000003275 alpha amino acid group Chemical group 0.000 description 13
239000000203 mixture Substances 0.000 description 13
108091028043 Nucleic acid sequence Proteins 0.000 description 12
230000015572 biosynthetic process Effects 0.000 description 12
150000007523 nucleic acids Chemical class 0.000 description 12
210000001519 tissue Anatomy 0.000 description 12
239000005557 antagonist Substances 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 11
108020004999 messenger RNA Proteins 0.000 description 11
102000039446 nucleic acids Human genes 0.000 description 11
108020004707 nucleic acids Proteins 0.000 description 11
239000000047 product Substances 0.000 description 11
102000005962 receptors Human genes 0.000 description 11
108020003175 receptors Proteins 0.000 description 11
206010061218 Inflammation Diseases 0.000 description 10
230000004054 inflammatory process Effects 0.000 description 10
230000003321 amplification Effects 0.000 description 9
238000005516 engineering process Methods 0.000 description 9
230000006870 function Effects 0.000 description 9
238000003199 nucleic acid amplification method Methods 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
108060003951 Immunoglobulin Proteins 0.000 description 8
241000700605 Viruses Species 0.000 description 8
230000027455 binding Effects 0.000 description 8
238000003745 diagnosis Methods 0.000 description 8
229940088598 enzyme Drugs 0.000 description 8
102000018358 immunoglobulin Human genes 0.000 description 8
239000000523 sample Substances 0.000 description 8
238000006467 substitution reaction Methods 0.000 description 8
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 7
208000020832 chronic kidney disease Diseases 0.000 description 7
238000001514 detection method Methods 0.000 description 7
238000011161 development Methods 0.000 description 7
238000009472 formulation Methods 0.000 description 7
108020001507 fusion proteins Proteins 0.000 description 7
102000037865 fusion proteins Human genes 0.000 description 7
238000009396 hybridization Methods 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
102000003886 Glycoproteins Human genes 0.000 description 6
108090000288 Glycoproteins Proteins 0.000 description 6
208000012902 Nervous system disease Diseases 0.000 description 6
208000008589 Obesity Diseases 0.000 description 6
210000000349 chromosome Anatomy 0.000 description 6
238000012217 deletion Methods 0.000 description 6
230000037430 deletion Effects 0.000 description 6
238000003780 insertion Methods 0.000 description 6
230000037431 insertion Effects 0.000 description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
239000003446 ligand Substances 0.000 description 6
239000012528 membrane Substances 0.000 description 6
235000020824 obesity Nutrition 0.000 description 6
239000002243 precursor Substances 0.000 description 6
238000000746 purification Methods 0.000 description 6
230000003248 secreting effect Effects 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
230000009261 transgenic effect Effects 0.000 description 6
229960005486 vaccine Drugs 0.000 description 6
108700028369 Alleles Proteins 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 5
230000008827 biological function Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
230000012010 growth Effects 0.000 description 5
150000002632 lipids Chemical class 0.000 description 5
230000035772 mutation Effects 0.000 description 5
208000023504 respiratory system disease Diseases 0.000 description 5
150000003384 small molecules Chemical class 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000005495 thyroid hormone Substances 0.000 description 5
229940036555 thyroid hormone Drugs 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
208000035143 Bacterial infection Diseases 0.000 description 4
241000283690 Bos taurus Species 0.000 description 4
206010009944 Colon cancer Diseases 0.000 description 4
108020004635 Complementary DNA Proteins 0.000 description 4
208000018522 Gastrointestinal disease Diseases 0.000 description 4
101710127721 Membrane protein Proteins 0.000 description 4
208000025966 Neurological disease Diseases 0.000 description 4
206010033645 Pancreatitis Diseases 0.000 description 4
108091058545 Secretory proteins Proteins 0.000 description 4
102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 description 4
208000036142 Viral infection Diseases 0.000 description 4
210000003050 axon Anatomy 0.000 description 4
208000022362 bacterial infectious disease Diseases 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
230000008859 change Effects 0.000 description 4
208000029742 colonic neoplasm Diseases 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
230000004069 differentiation Effects 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000004927 fusion Effects 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
230000028993 immune response Effects 0.000 description 4
208000027866 inflammatory disease Diseases 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
210000000653 nervous system Anatomy 0.000 description 4
238000011160 research Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
241000894007 species Species 0.000 description 4
239000000758 substrate Substances 0.000 description 4
102000011690 Adiponectin Human genes 0.000 description 3
108010076365 Adiponectin Proteins 0.000 description 3
102000008102 Ankyrins Human genes 0.000 description 3
108010049777 Ankyrins Proteins 0.000 description 3
102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
238000001712 DNA sequencing Methods 0.000 description 3
101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 3
101000835982 Homo sapiens SLIT and NTRK-like protein 5 Proteins 0.000 description 3
208000023105 Huntington disease Diseases 0.000 description 3
108090001061 Insulin Proteins 0.000 description 3
102000004877 Insulin Human genes 0.000 description 3
102000019298 Lipocalin Human genes 0.000 description 3
108050006654 Lipocalin Proteins 0.000 description 3
208000007452 Plasmacytoma Diseases 0.000 description 3
102000001253 Protein Kinase Human genes 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
102000006382 Ribonucleases Human genes 0.000 description 3
108010083644 Ribonucleases Proteins 0.000 description 3
102100029216 SLAM family member 5 Human genes 0.000 description 3
102100025501 SLIT and NTRK-like protein 5 Human genes 0.000 description 3
102100030326 Serpin B4 Human genes 0.000 description 3
108010023197 Streptokinase Proteins 0.000 description 3
102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
230000009471 action Effects 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
239000000556 agonist Substances 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
230000006907 apoptotic process Effects 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
210000001124 body fluid Anatomy 0.000 description 3
239000010839 body fluid Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000010367 cloning Methods 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
230000004064 dysfunction Effects 0.000 description 3
235000013601 eggs Nutrition 0.000 description 3
239000002158 endotoxin Substances 0.000 description 3
210000002919 epithelial cell Anatomy 0.000 description 3
210000003714 granulocyte Anatomy 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
230000001939 inductive effect Effects 0.000 description 3
108091008042 inhibitory receptors Proteins 0.000 description 3
208000014674 injury Diseases 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
238000002955 isolation Methods 0.000 description 3
108010013554 leupin Proteins 0.000 description 3
239000000463 material Substances 0.000 description 3
230000035800 maturation Effects 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
208000030159 metabolic disease Diseases 0.000 description 3
230000011987 methylation Effects 0.000 description 3
238000007069 methylation reaction Methods 0.000 description 3
238000013508 migration Methods 0.000 description 3
210000003097 mucus Anatomy 0.000 description 3
210000000822 natural killer cell Anatomy 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
-1 neurotropins Proteins 0.000 description 3
239000002245 particle Substances 0.000 description 3
108010091748 peptide A Proteins 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
210000002826 placenta Anatomy 0.000 description 3
230000001323 posttranslational effect Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
230000005855 radiation Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
238000007423 screening assay Methods 0.000 description 3
230000028327 secretion Effects 0.000 description 3
206010041823 squamous cell carcinoma Diseases 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000001890 transfection Methods 0.000 description 3
230000014616 translation Effects 0.000 description 3
230000032258 transport Effects 0.000 description 3
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
JVJUWEFOGFCHKR-UHFFFAOYSA-N 2-(diethylamino)ethyl 1-(3,4-dimethylphenyl)cyclopentane-1-carboxylate;hydrochloride Chemical compound Cl.C=1C=C(C)C(C)=CC=1C1(C(=O)OCCN(CC)CC)CCCC1 JVJUWEFOGFCHKR-UHFFFAOYSA-N 0.000 description 2
230000005730 ADP ribosylation Effects 0.000 description 2
208000004998 Abdominal Pain Diseases 0.000 description 2
102100030805 Adropin Human genes 0.000 description 2
244000063299 Bacillus subtilis Species 0.000 description 2
235000014469 Bacillus subtilis Nutrition 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
208000031229 Cardiomyopathies Diseases 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
208000029323 Congenital myotonia Diseases 0.000 description 2
102100024342 Contactin-2 Human genes 0.000 description 2
102100024325 Contactin-3 Human genes 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
201000003883 Cystic fibrosis Diseases 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
208000019505 Deglutition disease Diseases 0.000 description 2
108010053770 Deoxyribonucleases Proteins 0.000 description 2
102000016911 Deoxyribonucleases Human genes 0.000 description 2
238000012286 ELISA Assay Methods 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 2
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
208000002705 Glucose Intolerance Diseases 0.000 description 2
108010051696 Growth Hormone Proteins 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
101001064128 Homo sapiens Adropin Proteins 0.000 description 2
101000909516 Homo sapiens Contactin-2 Proteins 0.000 description 2
101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 2
101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 description 2
108010003272 Hyaluronate lyase Proteins 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
208000013016 Hypoglycemia Diseases 0.000 description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
239000004367 Lipase Substances 0.000 description 2
XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
108090000143 Mouse Proteins Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
208000010316 Myotonia congenita Diseases 0.000 description 2
108010063605 Netrins Proteins 0.000 description 2
102000010803 Netrins Human genes 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
102000019280 Pancreatic lipases Human genes 0.000 description 2
108050006759 Pancreatic lipases Proteins 0.000 description 2
102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 2
108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
101800001295 Putative ATP-dependent helicase Proteins 0.000 description 2
101800001006 Putative helicase Proteins 0.000 description 2
108010029176 Sialic Acid Binding Ig-like Lectin 1 Proteins 0.000 description 2
102100032855 Sialoadhesin Human genes 0.000 description 2
206010072170 Skin wound Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
102100038803 Somatotropin Human genes 0.000 description 2
241000187747 Streptomyces Species 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
108090000190 Thrombin Proteins 0.000 description 2
241000269370 Xenopus <genus> Species 0.000 description 2
241000269368 Xenopus laevis Species 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
238000007792 addition Methods 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
108010060162 alglucerase Proteins 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
208000022531 anorexia Diseases 0.000 description 2
239000000427 antigen Substances 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
238000013459 approach Methods 0.000 description 2
238000003491 array Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000008499 blood brain barrier function Effects 0.000 description 2
210000001218 blood-brain barrier Anatomy 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
230000004106 carbohydrate catabolism Effects 0.000 description 2
230000011712 cell development Effects 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000008614 cellular interaction Effects 0.000 description 2
230000005754 cellular signaling Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
210000004081 cilia Anatomy 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
206010061428 decreased appetite Diseases 0.000 description 2
230000007547 defect Effects 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
108010067396 dornase alfa Proteins 0.000 description 2
238000009509 drug development Methods 0.000 description 2
210000002472 endoplasmic reticulum Anatomy 0.000 description 2
230000037406 food intake Effects 0.000 description 2
235000012631 food intake Nutrition 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
239000000122 growth hormone Substances 0.000 description 2
210000003780 hair follicle Anatomy 0.000 description 2
210000003917 human chromosome Anatomy 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
230000002218 hypoglycaemic effect Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
208000003243 intestinal obstruction Diseases 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
229940040461 lipase Drugs 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
210000002751 lymph Anatomy 0.000 description 2
210000005171 mammalian brain Anatomy 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
238000013507 mapping Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000029052 metamorphosis Effects 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
229940116369 pancreatic lipase Drugs 0.000 description 2
244000045947 parasite Species 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
208000033808 peripheral neuropathy Diseases 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
102000054765 polymorphisms of proteins Human genes 0.000 description 2
230000004481 post-translational protein modification Effects 0.000 description 2
201000009104 prediabetes syndrome Diseases 0.000 description 2
239000002987 primer (paints) Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000009145 protein modification Effects 0.000 description 2
208000020016 psychiatric disease Diseases 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
201000000980 schizophrenia Diseases 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
108010088201 squamous cell carcinoma-related antigen Proteins 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
230000008685 targeting Effects 0.000 description 2
230000002123 temporal effect Effects 0.000 description 2
229960004072 thrombin Drugs 0.000 description 2
230000009466 transformation Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
230000005740 tumor formation Effects 0.000 description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
238000010798 ubiquitination Methods 0.000 description 2
230000034512 ubiquitination Effects 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
210000004340 zona pellucida Anatomy 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
208000009304 Acute Kidney Injury Diseases 0.000 description 1
208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
102000000905 Cadherin Human genes 0.000 description 1
108050007957 Cadherin Proteins 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
102100032145 Carbohydrate sulfotransferase 10 Human genes 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
108010007718 Chromogranins Proteins 0.000 description 1
102000007345 Chromogranins Human genes 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
208000000668 Chronic Pancreatitis Diseases 0.000 description 1
XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 description 1
108090001069 Chymopapain Proteins 0.000 description 1
208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
101710107712 Contactin-3 Proteins 0.000 description 1
206010011778 Cystinuria Diseases 0.000 description 1
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
206010012239 Delusion Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
208000027877 Disorders of Sex Development Diseases 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
208000014094 Dystonic disease Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
244000148064 Enicostema verticillatum Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
208000026019 Fanconi renotubular syndrome Diseases 0.000 description 1
201000006328 Fanconi syndrome Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
206010064571 Gene mutation Diseases 0.000 description 1
201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
108010049375 HNK-1 sulfotransferase Proteins 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
108010093488 His-His-His-His-His-His Proteins 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101100477562 Homo sapiens SIGLEC7 gene Proteins 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
102000009066 Hyaluronoglucosaminidase Human genes 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
206010020844 Hyperthermia malignant Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
208000032382 Ischaemic stroke Diseases 0.000 description 1
108060005987 Kallikrein Proteins 0.000 description 1
102000001399 Kallikrein Human genes 0.000 description 1
102100034870 Kallikrein-8 Human genes 0.000 description 1
101710176225 Kallikrein-8 Proteins 0.000 description 1
108010063045 Lactoferrin Proteins 0.000 description 1
102100032241 Lactotransferrin Human genes 0.000 description 1
108010047294 Lamins Proteins 0.000 description 1
102000006835 Lamins Human genes 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
102000016267 Leptin Human genes 0.000 description 1
108010092277 Leptin Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 1
208000007466 Male Infertility Diseases 0.000 description 1
208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
208000036626 Mental retardation Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
208000012905 Myotonic disease Diseases 0.000 description 1
206010068871 Myotonic dystrophy Diseases 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
108700019961 Neoplasm Genes Proteins 0.000 description 1
102000048850 Neoplasm Genes Human genes 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
101710131039 Opsin-5 Proteins 0.000 description 1
102100035591 POU domain, class 2, transcription factor 2 Human genes 0.000 description 1
101710084411 POU domain, class 2, transcription factor 2 Proteins 0.000 description 1
206010033649 Pancreatitis chronic Diseases 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
102000006877 Pituitary Hormones Human genes 0.000 description 1
108010047386 Pituitary Hormones Proteins 0.000 description 1
102100038124 Plasminogen Human genes 0.000 description 1
108010051456 Plasminogen Proteins 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
206010037742 Rabies Diseases 0.000 description 1
108090000244 Rat Proteins Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
101100108055 Rattus norvegicus Acsm3 gene Proteins 0.000 description 1
101100437545 Rattus norvegicus Arfgef1 gene Proteins 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
206010038540 Renal tubular necrosis Diseases 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
102000040739 Secretory proteins Human genes 0.000 description 1
108090000184 Selectins Proteins 0.000 description 1
102000003800 Selectins Human genes 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
101710187074 Serine proteinase inhibitor Proteins 0.000 description 1
108050000761 Serpin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
241000256248 Spodoptera Species 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
102000004896 Sulfotransferases Human genes 0.000 description 1
108090001033 Sulfotransferases Proteins 0.000 description 1
102000004385 Sulfurtransferases Human genes 0.000 description 1
108090000984 Sulfurtransferases Proteins 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
102000043168 TGF-beta family Human genes 0.000 description 1
108091085018 TGF-beta family Proteins 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102000007501 Thymosin Human genes 0.000 description 1
108010046075 Thymosin Proteins 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
208000000323 Tourette Syndrome Diseases 0.000 description 1
208000016620 Tourette disease Diseases 0.000 description 1
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
208000012998 acute renal failure Diseases 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
230000032683 aging Effects 0.000 description 1
229960003122 alglucerase Drugs 0.000 description 1
229960003318 alteplase Drugs 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
230000006229 amino acid addition Effects 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000010516 arginylation Effects 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
102000012265 beta-defensin Human genes 0.000 description 1
108050002883 beta-defensin Proteins 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
210000002459 blastocyst Anatomy 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000000872 buffer Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000009702 cancer cell proliferation Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229940015047 chorionic gonadotropin Drugs 0.000 description 1
230000014107 chromosome localization Effects 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
231100000868 delusion Toxicity 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
229960002086 dextran Drugs 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
229910003460 diamond Inorganic materials 0.000 description 1
239000010432 diamond Substances 0.000 description 1
230000029087 digestion Effects 0.000 description 1
102000038379 digestive enzymes Human genes 0.000 description 1
108091007734 digestive enzymes Proteins 0.000 description 1
238000012362 drug development process Methods 0.000 description 1
208000010118 dystonia Diseases 0.000 description 1
210000003981 ectoderm Anatomy 0.000 description 1
238000005868 electrolysis reaction Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
230000019439 energy homeostasis Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000002641 enzyme replacement therapy Methods 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
238000001400 expression cloning Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
150000002211 flavins Chemical class 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000022244 formylation Effects 0.000 description 1
238000006170 formylation reaction Methods 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
239000000417 fungicide Substances 0.000 description 1
230000006251 gamma-carboxylation Effects 0.000 description 1
238000003209 gene knockout Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
239000008187 granular material Substances 0.000 description 1
208000037824 growth disorder Diseases 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
101150097574 gsk gene Proteins 0.000 description 1
150000003278 haem Chemical group 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
201000011066 hemangioma Diseases 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
208000007386 hepatic encephalopathy Diseases 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
230000001632 homeopathic effect Effects 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
210000004754 hybrid cell Anatomy 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
238000012872 hydroxylapatite chromatography Methods 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
239000000960 hypophysis hormone Substances 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
208000021267 infertility disease Diseases 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
238000002372 labelling Methods 0.000 description 1
229940078795 lactoferrin Drugs 0.000 description 1
235000021242 lactoferrin Nutrition 0.000 description 1
210000005053 lamin Anatomy 0.000 description 1
239000002523 lectin Substances 0.000 description 1
229940039781 leptin Drugs 0.000 description 1
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
238000007443 liposuction Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
201000000564 macroglobulinemia Diseases 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
208000017517 male reproductive system disease Diseases 0.000 description 1
201000005857 malignant hypertension Diseases 0.000 description 1
201000007004 malignant hyperthermia Diseases 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
230000007102 metabolic function Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
238000002493 microarray Methods 0.000 description 1
150000002759 monoacylglycerols Chemical class 0.000 description 1
230000007659 motor function Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000007498 myristoylation Effects 0.000 description 1
239000002833 natriuretic agent Substances 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000008271 nervous system development Effects 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
230000014511 neuron projection development Effects 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
231100000618 neurotoxin Toxicity 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
230000003448 neutrophilic effect Effects 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
108010048477 olfactomedin Proteins 0.000 description 1
210000000196 olfactory nerve Anatomy 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
208000021090 palsy Diseases 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
208000029308 periodic paralysis Diseases 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
229940080469 phosphocellulose Drugs 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000010118 platelet activation Effects 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
210000002975 pon Anatomy 0.000 description 1
230000000270 postfertilization Effects 0.000 description 1
230000013823 prenylation Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000004952 protein activity Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
229940107568 pulmozyme Drugs 0.000 description 1
229940043131 pyroglutamate Drugs 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000006340 racemization Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
210000000463 red nucleus Anatomy 0.000 description 1
230000025915 regulation of apoptotic process Effects 0.000 description 1
206010038464 renal hypertension Diseases 0.000 description 1
238000012827 research and development Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000014860 sensory perception of taste Effects 0.000 description 1
239000003001 serine protease inhibitor Substances 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000003998 snake venom Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000007723 transport mechanism Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
210000002993 trophoblast Anatomy 0.000 description 1
206010044697 tropical sprue Diseases 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
108010047303 von Willebrand Factor Proteins 0.000 description 1
102100036537 von Willebrand factor Human genes 0.000 description 1
229960001134 von willebrand factor Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Reproductive Health (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Toxicology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Biophysics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Microbiology (AREA)
Pain & Pain Management (AREA)
General Engineering & Computer Science (AREA)

KR1020027014463A 2000-04-27 2001-04-26 신규 화합물 Withdrawn KR20030032940A (ko)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date
US19996300P	2000-04-27	2000-04-27
US60/199,963		2000-04-27
US20333600P	2000-05-11	2000-05-11
US60/203,336		2000-05-11
US20708700P	2000-05-25	2000-05-25
US60/207,087		2000-05-25
US20754600P	2000-05-26	2000-05-26
US60/207,546		2000-05-26

Publications (1)

Publication Number	Publication Date
KR20030032940A true KR20030032940A (ko)	2003-04-26

Family

ID=27498358

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020027014463A Withdrawn KR20030032940A (ko)	2000-04-27	2001-04-26	신규 화합물

Country Status (15)

Country	Link
EP (1)	EP1276755A4 (fr)
JP (1)	JP2003530869A (fr)
KR (1)	KR20030032940A (fr)
CN (1)	CN1439017A (fr)
AU (1)	AU2001257265A1 (fr)
BR (1)	BR0110402A (fr)
CA (1)	CA2407449A1 (fr)
CZ (1)	CZ20023548A3 (fr)
HK (1)	HK1053840A1 (fr)
HU (1)	HUP0300595A3 (fr)
IL (1)	IL152416A0 (fr)
MX (1)	MXPA02010692A (fr)
NO (1)	NO20025151L (fr)
PL (1)	PL358580A1 (fr)
WO (1)	WO2001081363A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20210052626A1 (en) *	2016-01-06	2021-02-25	Yeda Research And Development Co. Ltd.	Compositions and methods for treating malignant, autoimmune and inflammatory diseases

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7034132B2 (en)	2001-06-04	2006-04-25	Anderson David W	Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6558936B1 (en) *	1999-10-01	2003-05-06	Millennium Pharmaceuticals, Inc.	Human lipase proteins, nucleic acids encoding them, and uses of both of these
US6630335B1 (en)	2000-02-11	2003-10-07	Millennium Pharmaceuticals, Inc.	14171 protein kinase, a novel human protein kinase and uses thereof
NZ523122A (en) *	2000-06-22	2004-06-25	Smithkline Beecham Corp	Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases
US20030211515A1 (en) *	2000-06-30	2003-11-13	Lasek Amy K	Novel compounds
US6924364B2 (en)	2000-08-04	2005-08-02	Zymogenetics, Inc.	Human secreted protein, Zzp1
US7358353B2 (en)	2000-08-22	2008-04-15	Agensys, Inc.	Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
ES2395524T3 (es)	2000-08-22	2013-02-13	Agensys, Inc.	Acido nucleico y proteina correspondiente denominada 158P1D7 util para el tratamiento y la detección del cancer de vejiga y otros canceres
AU1181802A (en)	2000-09-27	2002-04-08	Curagen Corp	Novel proteins and nucleic acids encoding same
WO2002026826A2 (fr) *	2000-09-27	2002-04-04	Curagen Corporation	Nouvelles proteines et acides nucleiques codant pour celles-ci
EP1339847A2 (fr) *	2000-11-28	2003-09-03	Amgen, Inc.	Molecules associees au facteur de croissance transformant-beta et leurs applications
JP2004535161A (ja)	2001-03-08	2004-11-25	イミュネックス・コーポレーション	ヒト・セルピン・ポリペプチド
US6921807B2 (en)	2001-03-29	2005-07-26	Zymogenetics, Inc.	Proteinase inhibitor ZSERP9
US7033790B2 (en)	2001-04-03	2006-04-25	Curagen Corporation	Proteins and nucleic acids encoding same
US20020172995A1 (en) *	2001-05-17	2002-11-21	Wei Shao	Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
WO2003004527A2 (fr) *	2001-07-06	2003-01-16	Nsgene A/S	Nouveaux facteurs neurotrophiques
US20030215852A1 (en) *	2002-04-01	2003-11-20	Wyeth	Novel pancortin-Pablo protein interactions and methods of use thereof
AU2004210975B2 (en) *	2003-02-10	2008-04-10	Agensys, Inc.	Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
US7422906B2 (en)	2003-02-10	2008-09-09	Taisho Pharmaceutical Co., Ltd.	Apoptosis-inducing gene and utilization of the same
CA2534353A1 (fr) *	2003-08-01	2005-02-10	Zymogenetics, Inc.	Proteine zacrp11 liee au complement d'adipocyte
US7399469B2 (en)	2004-03-26	2008-07-15	Pdl Biopharma, Inc.	Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer
PT2887959T (pt)	2012-08-23	2019-02-01	Seattle Genetics Inc	Conjugados anticorpo-fármaco (adc) que se ligam a proteínas 158p1d7
CN108178797B (zh) *	2017-12-29	2020-12-01	西南大学	一种抗家蚕BmSRC多克隆抗血清、制备方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5830744A (en) *	1995-06-06	1998-11-03	Human Genome Sciences, Inc.	Gene encoding human Dnase
JPH09512715A (ja) *	1994-05-05	1997-12-22	ヒューマンジノームサイエンシーズ，インコーポレイテッド	ヒトｄｎａｓｅ
AU3395900A (en) *	1999-03-12	2000-10-04	Human Genome Sciences, Inc.	Human lung cancer associated gene sequences and polypeptides

2001
- 2001-04-26 WO PCT/US2001/013360 patent/WO2001081363A1/fr not_active Ceased
- 2001-04-26 CZ CZ20023548A patent/CZ20023548A3/cs unknown
- 2001-04-26 EP EP01930760A patent/EP1276755A4/fr not_active Withdrawn
- 2001-04-26 JP JP2001578451A patent/JP2003530869A/ja not_active Withdrawn
- 2001-04-26 MX MXPA02010692A patent/MXPA02010692A/es unknown
- 2001-04-26 PL PL01358580A patent/PL358580A1/xx unknown
- 2001-04-26 CA CA002407449A patent/CA2407449A1/fr not_active Abandoned
- 2001-04-26 AU AU2001257265A patent/AU2001257265A1/en not_active Abandoned
- 2001-04-26 IL IL15241601A patent/IL152416A0/xx unknown
- 2001-04-26 HK HK03104434.3A patent/HK1053840A1/zh unknown
- 2001-04-26 BR BR0110402-0A patent/BR0110402A/pt not_active IP Right Cessation
- 2001-04-26 KR KR1020027014463A patent/KR20030032940A/ko not_active Withdrawn
- 2001-04-26 HU HU0300595A patent/HUP0300595A3/hu unknown
- 2001-04-26 CN CN01811752A patent/CN1439017A/zh active Pending
2002
- 2002-10-25 NO NO20025151A patent/NO20025151L/no not_active Application Discontinuation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20210052626A1 (en) *	2016-01-06	2021-02-25	Yeda Research And Development Co. Ltd.	Compositions and methods for treating malignant, autoimmune and inflammatory diseases
US11986488B2 (en) *	2016-01-06	2024-05-21	Yeda Research And Development Co. Ltd.	Compositions and methods for treating malignant, autoimmune and inflammatory diseases

Also Published As

Publication number	Publication date
HUP0300595A2 (hu)	2003-06-28
NO20025151D0 (no)	2002-10-25
MXPA02010692A (es)	2003-03-10
CN1439017A (zh)	2003-08-27
CZ20023548A3 (cs)	2003-05-14
WO2001081363A1 (fr)	2001-11-01
EP1276755A4 (fr)	2004-03-31
CA2407449A1 (fr)	2001-11-01
HK1053840A1 (zh)	2003-11-07
AU2001257265A1 (en)	2001-11-07
JP2003530869A (ja)	2003-10-21
NO20025151L (no)	2002-12-13
IL152416A0 (en)	2003-05-29
BR0110402A (pt)	2003-02-11
HUP0300595A3 (en)	2007-06-28
EP1276755A1 (fr)	2003-01-22
PL358580A1 (en)	2004-08-09

Publication	Publication Date	Title
KR20030032940A (ko)	2003-04-26	신규 화합물
US20010012628A1 (en)	2001-08-09	sbgFGF-19a
US20090192294A1 (en)	2009-07-30	Magi polynucleotides, polypeptides, and antibodies
NZ524328A (en)	2004-09-24	A protein with homology to relaxin
US20050255557A1 (en)	2005-11-17	Novel compounds
US20050260668A1 (en)	2005-11-24	Novel compounds
KR20030021178A (ko)	2003-03-12	신규 화합물
US20050255558A1 (en)	2005-11-17	Novel compounds
US6426197B1 (en)	2002-07-30	Polynucleotides encoding a human potassium channel
US20050214905A1 (en)	2005-09-29	Novel compounds
US6183990B1 (en)	2001-02-06	Compounds
US20030175805A1 (en)	2003-09-18	Human wingless-like gene
US20050260714A1 (en)	2005-11-24	Novel compounds
US6274380B1 (en)	2001-08-14	Cacnglike3 polynucleotides and expression systems
WO2001014423A1 (fr)	2001-03-01	Identification de trois peptides de canaux de calcium putatifs possedant une activite de vanilrep5
ZA200208657B (en)	2003-08-11	Novel compounds.
US20040072999A1 (en)	2004-04-15	Novel protein inhibitor of apoptosis proteins
US20040072172A1 (en)	2004-04-15	Scramblase 2
US20070292921A1 (en)	2007-12-20	tRNA synthetases, metRS
GB2365010A (en)	2002-02-13	Human TREK2 polypeptides
US20020004223A1 (en)	2002-01-10	FHAR1, a new ring finger protein
US20040073004A1 (en)	2004-04-15	Polynucleotides and polypeptides encoded thereby
US20060205641A1 (en)	2006-09-14	VANILREP4 polypeptides and VANILREP4 polynucleotides
US20030148446A1 (en)	2003-08-07	Acute neuronal induced calcium binding protein type 1 ligand
EP1170365A1 (fr)	2002-01-09	Un membre de la famille des polypeptides de canal ionique; vanilrep4

Legal Events

Date	Code	Title	Description
2002-10-26	PA0105	International application	Patent event date: 20021026 Patent event code: PA01051R01D Comment text: International Patent Application
2003-04-26	PG1501	Laying open of application
2006-04-27	PC1203	Withdrawal of no request for examination
2006-04-27	WITN	Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid